Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402428 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
A Phase 3 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,331
- Enrollment target
NCT00402428 is a Phase 3 study that has completed, run by Human Genome Sciences. The registered enrollment target is 1,331 participants.
The verdict
NCT00402428, a Phase 3 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,331 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 1 who are IFNa treatment naive.
Interventions
- DRUG Ribavirin
- DRUG albumin interferon alfa-2b
- DRUG peginterferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402428
The ClinicalTrials.gov registry entry for NCT00402428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT00402428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402428 about?
NCT00402428 is a clinical study titled "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients". This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 1 who ar...
What is the current status of trial NCT00402428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,331 participants. The study started on 2006-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00402428?
The interventions under investigation include: Ribavirin (DRUG), albumin interferon alfa-2b (DRUG), peginterferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT00402428?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.